Novacure Pharmaceutical India Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 20-12-2024
- Paid Up Capital ₹ 0.20 M
as on 20-12-2024
- Company Age 8 Year, 1 Month
- Last Filing with ROC 31 Mar 2018
- Revenue %
(FY 2018)
- Profit -4245.77%
(FY 2018)
- Ebitda -3464.41%
(FY 2018)
- Net Worth -771.11%
(FY 2018)
- Total Assets 4517.62%
(FY 2018)
About Novacure Pharmaceutical India
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2018. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.20 M, as per Ministry of Corporate Affairs (MCA) records.
Jayesh Sanklecha, Madan Choudhary, and Varsha Jain serve as directors at the Company.
- CIN/LLPIN
U74999PN2016PTC167362
- Company No.
167362
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Dec 2016
- Date of AGM
29 Sep 2018
- Date of Balance Sheet
31 Mar 2018
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Novacure Pharmaceutical India?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jayesh Sanklecha  | Managing Director | 02-Dec-2016 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Madan Choudhary | Director | 01-Apr-2017 | Current |
| Varsha Jain | Director | 02-Dec-2016 | Current |
Financial Performance of Novacure Pharmaceutical India.
Novacure Pharmaceutical India Private Limited, for the financial year ended 2018, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 4245.77% decrease in profit. The company's net worth observed a substantial decline by a decrease of 771.11%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Novacure Pharmaceutical India?
In 2018, Novacure Pharmaceutical India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Laksh Publishing House Private LimitedActive 10 years 1 monthJayesh Sanklecha and Varsha Jain are mutual person
- Novacure India Private LimitedActive 8 years 5 months
Jayesh Sanklecha, Madan Choudhary and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Novacure Pharmaceutical India?
Unlock and access historical data on people associated with Novacure Pharmaceutical India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Novacure Pharmaceutical India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Novacure Pharmaceutical India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
